Lakewood-Amedex Inc (“Lakewood-Amedex” or the “Company”) is a unique organization seldom found in the current climate of high through put drug discovery and development. Lakewood-Amedex’s broad portfolio of therapeutics is the culmination of many years of targeted research aimed at treating infectious disease and improving human health. Scientists now predict that within the next ten years, infectious disease will become the greatest threat to human health.
Lakewood-Amedex, a private development stage biopharmaceutical company, headquartered in Sarasota, Florida, has a diverse portfolio of targeted therapeutics, broad spectrum anti-bacterials, and anti-viral technologies.
· NuBiotics, first in class broad spectrum anti-bacterial compounds, are under development for the treatment of serious bacterial infectious. The lead compound, designated Nu2, is scheduled to enter phase I trial in early 2011 and represents a first line defence against the increasing number of antibiotic resistant bacteria.
· A proprietary platform technology, termed nanoRNA, developed for the treatment of viral and chronic human diseases that will support the long term growth of the product pipeline.
· The targeted therapeutic HUS-MAb, which is a fully human toxin-neutralizing monoclonal antibody, shown to be effective in the treatment of hemolytic uremic syndrome (HUS) caused by pathogenic Ecoli O157:H7.